Biogen Inc. stock underperforms Tuesday when compared to competitors
Biogen Inc. (BIIB) shares fell 1.32% to $205.70 on Tuesday, underperforming the broader stock market, which also saw declines in the S&P 500 Index and Dow Jones Industrial Average. This marks the second consecutive day of losses for the stock.
Why Biogen (BIIB) is Poised to Beat Earnings Estimates Again
Biogen Inc. (BIIB) is expected to continue its streak of beating earnings estimates, according to Zacks Equity Research. The company has a strong record of exceeding expectations in its last two reports, with an average surprise of 22.31%. Combined with a positive Zacks Earnings ESP of +0.22% and a Zacks Rank #3 (Hold), these indicators suggest a high probability of another earnings beat in its upcoming report on July 29, 2026.
Will Travere’s Removal From Key Russell Value Indices Change Travere Therapeutics' (TVTX) Narrative?
Travere Therapeutics (TVTX) was recently removed from several Russell value and small-cap indices in late June 2026. This action could lead to forced portfolio rebalancing by index-tracking funds and reshape the company's investment narrative and risk profile, despite its core growth driver, FILSPARI, receiving expanded FDA approval in April 2026. While operational progress continues with FILSPARI for rare kidney diseases, investors are advised to consider the implications of the index removal on broader market perception and potential payer scrutiny regarding drug pricing.
Why Biogen (BIIB) is Poised to Beat Earnings Estimates Again
Biogen Inc. (BIIB) is expected to continue its streak of beating earnings estimates, driven by its positive Zacks Earnings ESP of +0.22% and a Zacks Rank #3 (Hold). The company has a history of exceeding earnings expectations, with an average surprise of 22.31% over the last two quarters. This combination suggests a high probability of another positive surprise in its upcoming earnings report on July 29, 2026.
Biogen to Webcast from the Alzheimer's Association International Conference (AAIC) July 14, 2026
Biogen Inc. announced it will host an investor webcast on Tuesday, July 14, 2026, at 12:00 p.m. ET, from the Alzheimer's Association International Conference (AAIC) in London. The live webcast will feature Biogen management and will be accessible via the investors section of Biogen’s website, with an archived version available for 90 days. The announcement was made on July 7, 2026.
Jefferies Adjusts Price Target on Biogen to $255 From $210
Jefferies has increased its price target for Biogen (BIIB) from $210 to $255. This adjustment was published on July 7, 2026, at 05:34 am EDT by MT Newswires, indicating a more optimistic outlook on the pharmaceutical company's stock by the firm.
Amyotrophic Lateral Sclerosis Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma
The Amyotrophic Lateral Sclerosis (ALS) market is projected to grow significantly by 2036, driven by an increasing disease prevalence, advancements in drug development, and rising regulatory support. Key companies like Helixmith, Sanofi, and Biogen are actively developing new therapies, with several receiving Orphan Drug or Fast Track designations from the FDA. Despite challenges such as complex disease biology and high clinical trial failure rates, the focus on precision medicine and R&D investments is poised to transform the treatment landscape for ALS.
Biogen Inc (MEX:BIIB) Stock Price, Trades & News
This article provides a detailed stock summary page for Biogen Inc (MEX:BIIB), covering its current stock price, key financial metrics like P/E ratio, market cap, and enterprise value. It also includes an overview of the company's business description as a biopharmaceutical firm focused on neurodegenerative and rare diseases, along with various financial strength, growth, profitability, and valuation ranks. The page highlights warning signs detected by GuruFocus and lists upcoming stock events and recent press releases related to the company.
Biogen Inc (BIIB) Shares Fall 3.5% -- GF Value Says Still Overva
Biogen Inc (BIIB) shares dropped 3.5% to $208.46, yet GuruFocus's GF Value continues to indicate the stock is overvalued by 8.7% compared to its intrinsic value of $191.80. The company's GF Score is 73/100, reflecting strong financial health and profitability but weak growth prospects, and its P/E ratio of 22.4x is significantly higher than its historical median. The absence of insider transactions over the last three months also suggests a cautious stance among company executives.
Biogen Inc (BIIB) Shares Fall 3.5% -- GF Value Says Still Overvalued
Biogen Inc (BIIB) shares fell 3.5% on July 6, 2026, to $208.46, but are still considered overvalued by GuruFocus's GF Value, trading 8.7% above its intrinsic value of $191.80. The company's GF Score is 73/100, indicating strong financial health and profitability but weaker growth prospects. Despite a positive year-to-date and past-year performance, the elevated P/E ratio and lack of recent insider transactions suggest caution for investors.
DNLI - Denali Therapeutics Inc Volatility & Greeks
This article provides a detailed financial overview of Denali Therapeutics Inc. (DNLI), including its latest stock performance, key financial ratios, volatility metrics, and insider/institutional ownership data. It covers various performance indicators like EPS, sales growth, and trading volumes, alongside analyst recommendations and target prices.
FDMT - 4D Molecular Therapeutics Inc Revenue Breakdown
This article provides a detailed financial breakdown for 4D Molecular Therapeutics Inc. (FDMT), including key metrics such as market cap, sales, income, EPS, and various performance indicators. It also lists insider and institutional ownership, short interest, and analyst recommendations.
Roche pens $490m Astex breast cancer license deal
Roche's subsidiary, Genentech, has signed a global drug discovery and licensing deal with UK biotech Astex Pharmaceuticals for breast cancer drugs. Roche will provide $25 million upfront and potential payments exceeding $465 million based on milestones, along with tiered royalties. This collaboration aims to identify new preclinical candidates for breast cancer treatment, with Genentech leading development and commercialization. The deal highlights Roche's continuing investment in oncology and the growing presence of the UK life sciences sector.
Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Can Afford To Invest In Growth
This article analyzes SELLAS Life Sciences Group's financial position, specifically its cash reserves and burn rate. It concludes that despite having substantial cash, the company's high burn rate means it can only fund current operations for a little over a year without seeking additional financing.
Ionis completes enrollment in Angelman syndrome drug trial
Ionis Pharmaceuticals Inc. announced the completion of enrollment in the pivotal cohort of its Phase 3 REVEAL study for obudanersen, a drug targeting Angelman syndrome. The company anticipates topline data in the second half of 2027 and plans to initiate another Phase 3 study (CHAMPION) for different genotypes. This comes as Ionis's stock trades near its 52-week high, and the company recently received FDA approval for Tryngolza for severe hypertriglyceridemia, drawing positive analyst ratings.
How AAIC 2026 Alzheimer’s Data Releases Could Reframe Biogen (BIIB) Investors’ Long‑Term Thesis
Biogen plans to present new clinical, biomarker, and safety data for its Alzheimer's portfolio at AAIC 2026, including Phase 2 results for diranersen and expanded real-world evidence for LEQEMBI. These data releases, particularly for diranersen, are expected to significantly influence investors' long-term assessment of Biogen's Alzheimer's treatment potential and portfolio balance. The company's Alzheimer's franchise is crucial for offsetting pressures on older drugs, though rising R&D charges from recent acquisitions pose a near-term earnings risk.
Cantor Fitzgerald reiterates Amgen stock Neutral rating at $350
Cantor Fitzgerald has reiterated a Neutral rating on Amgen Inc. (NASDAQ:AMGN) with a $350 price target, despite expectations of a strong quarterly earnings driven by Repatha and Uplizna performance. The firm noted that Amgen's pipeline lacks significant drivers to extend its recent stock momentum, which has seen shares rise over 10% since June. While InvestingPro analysis suggests Amgen is undervalued with a Fair Value of $394, Cantor Fitzgerald believes a good earnings report alone won't lead to a substantial re-rating given upcoming patent expirations and other pipeline issues.
HSBC Adjusts Price Target on Biogen to $157 From $150
HSBC has increased its price target for Biogen (BIIB) shares to $157 from $150, as reported by MT Newswires. The adjustment was published on July 6, 2026, at 07:46 am EDT. Biogen's stock closed at $216.12 on July 1, 2026, having shown a +22.80% change year-to-date.
FDA deepens Vertex's Casgevy label, opening treatment for patients as young as 2
The FDA has expanded the label for Vertex's gene therapy Casgevy, co-developed with CRISPR Therapeutics, to include patients as young as two years old for sickle cell disease and beta thalassemia. This expansion opens treatment to an additional 5,500 children in the U.S., offering earlier intervention to prevent cumulative organ damage. The decision is supported by positive results from ongoing phase 3 trials in pediatric populations.
Claim your share of the $18.9M Biogen securities class action settlement
Investors who purchased Biogen Inc. common stock between June 8, 2021, and July 12, 2021, may be eligible to claim a portion of an $18.9 million class action settlement. The lawsuit alleged that Biogen and its executives made misleading statements regarding the pricing and Medicare coverage of its Alzheimer's drug, Aduhelm, causing stock prices to be artificially inflated. Class members can file claims online or via mail by September 24, 2026, with an estimated recovery of around $1.36 per eligible share.
ACAD - Acadia Pharmaceuticals Inc Forecast, Target Price
This article provides comprehensive financial data for Acadia Pharmaceuticals Inc. (ACAD), including key metrics like market capitalization, P/E ratio, EPS forecasts, and sales performance. It also details insider and institutional ownership, profitability ratios, and various stock performance indicators, alongside an analyst consensus target price of $32.30.
ALKS - Alkermes plc Volatility & Greeks
This article provides a detailed financial overview of Alkermes plc (ALKS), including its stock performance, key financial ratios, and volatility metrics. It lists various financial data points like market capitalization, sales, income, P/E ratio, and recent stock performance over different periods. The data covers profitability, efficiency ratios, and insider/institutional ownership, alongside volatility and Greek parameters relevant to options trading.
Why Vor Biopharma (VOR) Is Up 27.9% After Broad Russell Index Inclusion And What's Next
Vor Biopharma Inc. (VOR) recently saw its stock rise by 27.9% following its inclusion in several Russell indexes. This inclusion enhances the company's visibility and liquidity, but its core investment risks, such as funding the pipeline without further dilution given significant net losses and negative equity, remain unchanged. Future performance heavily depends on clinical progress, regulatory news, and financial updates, with current valuations suggesting potential overvaluation.
DNLI - Denali Therapeutics Inc Latest SEC Filings
This page provides a detailed financial overview and snapshot of Denali Therapeutics Inc. (DNLI), including its latest stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It also lists the company's SEC filings and provides a general market overview for the biotechnology sector.
Biogen's $1 Billion Bet: A Venture-Style Pivot to Undisclosed Immunology
Biogen is acquiring RayThera Inc. for up to $1 billion, a strategic move reflecting a pivot towards early-stage, high-upside immunology assets with a "venture-style" milestone-driven payment structure. This aggressive pipeline replenishment is critical for securing long-term growth beyond 2030, following recent challenges and patent expirations. While the inherent risks of early-stage drug development and undisclosed mechanisms exist, this calculated gamble aims to transform Biogen's future with a new generation of therapeutic growth.
VRTX - Vertex Pharmaceuticals Inc Options
This article provides a detailed financial overview of Vertex Pharmaceuticals Inc (VRTX), including its stock performance, market capitalization, income, sales, and various financial ratios. It also highlights institutional and insider ownership, profitability margins, and analyst recommendations, offering a comprehensive snapshot of the company's financial health and market position.
Is Vertex Pharmaceuticals (VRTX) Undervalued After CASGEVY Won Expanded FDA Approval?
Vertex Pharmaceuticals (VRTX) is gaining attention after the FDA expanded the use of its gene-editing therapy, CASGEVY, for younger patients with sickle cell disease or beta thalassemia. Despite recent share price gains, Simply Wall St's narrative suggests VRTX is still undervalued, with a fair value estimate of $547.72 against a current trading price of $528.04. The analysis highlights projected revenue and profit margin growth, though it cautions that future success depends on pipeline execution and pricing stability.
NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema
Shares of Nektar Therapeutics (NKTR) surged 10% as investors anticipate upcoming clinical data for its lead drug, rezpegaldesleukin, aimed at autoimmune and inflammatory diseases. The company plans to initiate late-stage trials for atopic dermatitis by the end of July 2026 and expects to present more data from its mid-stage eczema study in the latter half of 2026, alongside further alopecia areata developments. Nektar's strong financial position, with over a billion dollars in cash and investments, is expected to fund operations until 2028.
10 Most Undervalued NASDAQ Stocks to Buy Right Now
This article identifies Diamondback Energy Inc. (NASDAQ: FANG) as one of the 10 most undervalued NASDAQ stocks to buy right now. It highlights the recent acquisition by its subsidiary, Viper Energy, of mineral and royalty interests, expanding its presence in the Permian Basin. Diamondback Energy is an independent American oil and natural gas company focused on unconventional onshore oil and gas reserves in West Texas.
10 Most Undervalued NASDAQ Stocks to Buy Right Now
This article lists the 10 most undervalued NASDAQ stocks, focusing on Diamondback Energy Inc. (NASDAQ: FANG) as an example. It highlights the recent acquisition by its subsidiary, Viper Energy, which is expanding its mineral and royalty holdings in the Permian Basin. The piece emphasizes Diamondback Energy's focus on unconventional oil and gas reserves in West Texas.
GMAB - Genmab ADR Earnings
This Finviz article provides a detailed financial overview of Genmab ADR (GMAB), including its last closing price, key financial metrics like market cap, income, sales, P/E ratio, and EPS. It also lists performance indicators, insider ownership, institutional ownership, and analyst recommendations. The data highlights recent stock performance and valuation figures for the biotechnology company.
GRFS - Grifols SA ADR Short Interest
This article provides a detailed overview of Grifols SA ADR (GRFS) stock, focusing on its short interest and various financial metrics. It includes data on market capitalization, income, sales, dividends, P/E ratio, EPS growth, insider and institutional ownership, profitability margins, and price performance over different periods. The stock closed at $7.16, showing a slight increase, with a short float of 2.33% and a short interest of 6.01 million shares.
Biogen (BIIB) Could Be 1% Undervalued Before Key AAIC Alzheimer’s Data
Biogen (BIIB) is set to present crucial data at the Alzheimer's Association International Conference (AAIC), focusing on its diranersen Phase 2 results and real-world evidence for LEQEMBI. The stock is currently considered about 1.4% undervalued with a fair value of $219.27, according to Simply Wall St's valuation narrative. Investors are evaluating whether the potential upside from these Alzheimer's treatments is already priced into the stock, especially given its recent 62.66% increase over the past year.
GHRS - GH Research PLC Options
This article provides a comprehensive financial overview of GH Research PLC (GHRS), detailing its stock performance, key financial metrics, and insider/institutional ownership. It highlights the company's recent closing price, market capitalization, earnings per share, and various performance indicators over different periods.
NBTX - Nanobiotix ADR Dividends
This article provides detailed financial data and performance metrics for Nanobiotix ADR (NBTX). It covers key financial figures such as market cap, income, sales, and various ratios, along with stock performance over different periods. The data indicates strong past performance in sales and stock price, but also highlights negative income and profitability margins.
XENE - Xenon Pharmaceuticals Inc Volatility & Greeks
This article provides a detailed financial overview of Xenon Pharmaceuticals Inc. (XENE), including its latest stock performance, key financial metrics, volatility indicators, and analyst recommendations. It highlights the company's market capitalization, income, sales, and various financial ratios, alongside insider and institutional ownership data.
GRFS - Grifols SA ADR Volatility & Greeks
This article provides a comprehensive financial overview of Grifols SA ADR (GRFS), detailing its stock performance, volatility, and key financial ratios. It includes data on market capitalization, income, sales, dividend information, and analyst recommendations. The report also highlights insider and institutional ownership, short interest, and various profitability margins.
BHVN - Biohaven Ltd Latest SEC Filings
This article provides the latest SEC filing details for Biohaven Ltd (BHVN), including its stock performance, key financial metrics, insider and institutional ownership, and valuation ratios. The company has a market cap of $2.40 billion and shows significant institutional ownership, along with recent stock appreciation over various periods.
BBOT SEC Filings - BridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms
This article provides a comprehensive overview of BridgeBio Oncology Therapeutics, Inc. (BBOT) SEC filings, including 10-K, 10-Q, and 8-K forms, catering to investors and traders. It details several recent filings such as a Q3 2025 loss and liquidity report, an 8-K announcing quarterly results, and information on insider share acquisitions and equity plan registrations. The platform, StockTitan, offers AI-generated summaries, impact scoring, and sentiment analysis for each filing.
Vertex (VRTX) Just Won FDA Approval To Treat 5,500 More Young Children
Vertex Pharmaceuticals (VRTX) has received FDA approval for its CASGEVY gene therapy to treat sickle cell disease and transfusion-dependent beta thalassemia in children as young as two years old. This approval expands the eligible pediatric population by approximately 5,500 children in the U.S., marking a significant step in the company's diversification beyond cystic fibrosis treatments. Investors will be watching the adoption rate, reimbursement, and long-term safety data as CASGEVY expands into this younger demographic.
REGENXBIO Inc updates pipeline strategy as gene therapy sector evolves
REGENXBIO Inc is a clinical-stage biotechnology company focusing on developing gene therapies for neurological and ophthalmological conditions. The company's strategy involves advancing its pipeline through clinical trials and seeking collaborations, operating within a biotech sector influenced by capital access and clinical data. REGENXBIO aims to address the genetic causes of serious diseases, with its stock performance tied to sector sentiment and trial updates.
MDGL - Madrigal Pharmaceuticals Inc Latest SEC Filings
This article provides a detailed financial snapshot of Madrigal Pharmaceuticals Inc. (MDGL), including its latest stock performance, key financial metrics, insider and institutional ownership data, and various valuation ratios. It covers aspects like market capitalization, sales, earnings per share, and stock performance over different periods.
GRFS - Grifols SA ADR Latest SEC Filings
This article provides comprehensive financial data and performance metrics for Grifols SA ADR (GRFS). It covers key financial figures like market cap, income, sales, and various ratios, along with stock performance metrics, insider ownership, analyst recommendations, and recent SEC filing information.
H.C. Wainwright Remains a Buy on Biogen (BIIB)
H.C. Wainwright analyst Ananda Ghosh reiterated a Buy rating on Biogen (BIIB) with a price target of $237.00. This follows similar positive sentiment from Needham, while Morgan Stanley maintained a Hold rating. Biogen recently reported Q1 revenues of $2.48 billion and a net profit of $319.5 million, an increase from the previous year.
H.C. Wainwright Remains a Buy on Biogen (BIIB)
H.C. Wainwright maintained a Buy rating on Biogen (BIIB) with a price target of $237.00. This rating was echoed by Needham's Ami Fadia, while Morgan Stanley holds a Neutral stance. Biogen reported increased quarterly revenue and net profit in its latest earnings release for Q1, ending March 31, 2026.
BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peers
Jay Woods, chief global strategist at Freedom Capital Markets, recommends Biogen (BIIB) as his top pick in the biotech sector due to its diversified focus across autoimmune kidney diseases and Alzheimer's, unlike many peers reliant on single drug breakthroughs. Shares of Biogen rose 3.04% and analysts expect further upside, despite anticipated non-recurring charges in Q2 and Q3 2026. The company awaits key data for its Alzheimer's drug diranersen and a potential FDA approval for a new LEQEMBI dosing option.
Satellos Bioscience Fast Track Win Fuels DMD Hopes
Satellos Bioscience's SAT-3247, a treatment for Duchenne muscular dystrophy (DMD), has received FDA Fast Track designation, aiming to accelerate its regulatory review. The DMD market is projected for significant growth, reaching US$62.13 billion by 2030, presenting a substantial opportunity for innovative therapies like Satellos's oral small-molecule drug. Several analysts have issued strong buy ratings for Satellos, citing its differentiated approach and upcoming Phase 2 data readouts as key catalysts.
BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peers
Jay Woods, chief global strategist at Freedom Capital Markets, has highlighted Biogen Inc. (BIIB) as his top biotech pick, noting its multiple focuses across autoimmune kidney diseases and Alzheimer’s, which provides more stability than companies relying on a single drug breakthrough. Biogen shares rose 3.04% on Thursday, with Woods suggesting further upside potential despite anticipated non-recurring charges in Q2 and Q3 2026. Investors are awaiting mid-stage data for its Alzheimer's drug diranersen and an FDA decision on a subcutaneous starting dose for LEQEMBI, with Needham and Morgan Stanley recently raising their price targets for the stock.
BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peers
Jay Woods, chief global strategist at Freedom Capital Markets, has recommended investing in the biotech sector, specifically picking Biogen Inc. (BIIB) due to its diversified focus across autoimmune kidney diseases and Alzheimer's, unlike many peers that rely on a single drug. Biogen shares ended Thursday's session 3.04% higher, and the company has several upcoming catalysts, including detailed mid-stage data for its Alzheimer's drug diranersen and a potential FDA decision for a weekly at-home starting dose of LEQEMBI. Despite projecting non-recurring charges in Q2 and Q3 2026, Woods believes the stock's turnaround is truly beginning, with shares still significantly below their 2021 all-time high.
REGN - Regeneron Pharmaceuticals Inc Latest SEC Filings
This article provides a detailed financial overview of Regeneron Pharmaceuticals Inc (REGN), including its latest stock performance, key financial metrics, and company statistics. It covers various aspects like market capitalization, income, sales, dividend information, analyst recommendations, and performance across different timeframes.
